+357 96 030922
info@marketpublishers.com

Prostate Cancer Biomarkers Market Size, Share & Trends Analysis Report By Type (Genetic Biomarkers, Cell-based Biomarkers, Metabolomic Biomarkers), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

https://marketpublishers.com/r/PD58C1F97E02EN.html
Date: April 2025
Pages: 120
Price: US$ 5,950.00 (Single User License)
ID: PD58C1F97E02EN

Abstracts

This report can be delivered to the clients within 2 Business days

Prostate Cancer Biomarkers Market Growth & Trends

The global prostate cancer biomarkers market size is expected t%li%reach USD 9.8 billion by 2030, registering a CAGR of 13.1% from 2025 t%li%2030, according t%li%a new report by Grand View Research, Inc. The market is undergoing rapid evolution driven by the increasing demand for precision diagnostics and the limitations of conventional screening methods like PSA testing. PSA, while widely used, has low specificity, often leading t%li%overdiagnosis and overtreatment. As a result, there is a significant shift towards molecular and genomic biomarkers that can offer improved diagnostic accuracy and guide clinical decisions. Emerging biomarkers such as PCA3 (Prostate Cancer Antigen 3), 4Kscore, and ConfirmMDx have demonstrated superior performance in risk stratification and biopsy decision support. These tests are increasingly being integrated int%li%clinical practice t%li%reduce unnecessary biopsies and improve patient outcomes.

A key market driver is the growing focus on personalized medicine. Genomic classifiers like Decipher and Oncotype DX GPS help determine the aggressiveness of prostate tumors and inform treatment planning, especially in early-stage patients deciding between active surveillance and intervention. Liquid biopsy-based technologies are als%li%gaining attention for their non-invasive nature, with urine-based tests like

+357 96 030922
info@marketpublishers.com

SelectMDx and ExoDx offering clinically actionable insights for patients with elevated PSA. These innovations are particularly relevant in cases where traditional biopsies carry risks or yield inconclusive results.

Technological advancements in next-generation sequencing (NGS) and transcriptomics are further accelerating biomarker discovery. For example, studies have identified gene fusions such as TMPRSS2-ERG and mutations in BRCA1/2 and ATM as significant markers for prognosis and therapeutic guidance. The increasing use of these biomarkers in selecting patients for targeted therapies like PARP inhibitors reflects the rising importance of companion diagnostics in the treatment ecosystem. Moreover, metabolomic biomarkers, which analyze small-molecule metabolic changes associated with tumor progression, are emerging as promising tools for early detection and monitoring.

However, the market still faces several challenges. Standardization across biomarker assays remains limited, and there is a lack of consensus among clinicians regarding which tests t%li%adopt and at what clinical stages. Reimbursement issues and cost concerns can hinder the routine use of advanced biomarker tests, particularly in regions with constrained healthcare budgets. Furthermore, regulatory pathways for biomarker approval are often lengthy, which can delay commercial availability. Even as newer tests enter the market, widespread clinical adoption requires large-scale validation studies and integration int%li%existing clinical workflows.

Despite these barriers, the prostate cancer biomarker industry presents notable growth opportunities. Collaborations between academia and industry are intensifying, aimed at discovering and validating novel biomarker panels. With increasing awareness of the limitations of PSA and growing emphasis on value-based care, there is strong momentum t%li%shift toward more informative, less invasive diagnostics. In this context, biomarkers like AR-V7, used for monitoring treatment resistance in advanced prostate cancer, illustrate the potential of biomarker-guided therapy selection.

As the field continues t%li%advance, prostate cancer diagnostics are moving toward a more integrated and individualized model, where molecular insights guide not only early detection but als%li%therapeutic decisions and long-term management strategies.

Some of the key players in the market are Exact Sciences, Myriad Genetics, Bio-Techne, Olympus Corporation, OPKO Health. These players are involved in various strategic initiatives such as product launch and approval in order t%li%cater t%li%a global clientele. For instance, in December 2024, Myriad Genetics’ Prolaris test

+357 96 030922
info@marketpublishers.com

continues t%li%be recognized by the National Comprehensive Cancer Network (NCCN) as an Advanced Tool for prostate cancer prognosis. It remains included in the NCCN guidelines with a Category 2A evidence level, indicating strong support (?85%) from the NCCN prostate panel. This classification reinforces Prolaris' clinical relevance in helping guide treatment decisions based on tumor aggressiveness.

Prostate Cancer Biomarker Market Report Highlights

Based on type, protein biomarkersaccounted for largest revenue share of 57.73% in 2024. The protein biomarkers segment in the prostate cancer biomarkers market is driven by the widespread clinical use of PSA and PHI tests, rising prostate cancer prevalence, and strong clinical guideline support. Technological advances in multiplex assays and risk stratification tools like the 4Kscore enhance diagnostic accuracy. Additionally, increased demand for non-invasive, cost-effective, and point-of-care testing solutions fuels further growth in this segment across both developed and emerging markets.

Based on application screening and early detection dominated the market and accounted for the largest share of 45.14% in 2024.The screening and early detection segment in the market is driven by rising disease prevalence, aging populations, and adoption of non-invasive tests. For example, PSA testing remains a global standard, while PHI (Prostate Health Index) and the 4Kscore offer improved specificity, reducing unnecessary biopsies. Programs like the U.S. Preventive Services Task Force (USPSTF) recommendation for PSA testing in men aged 55–69 further boost demand. Increased public awareness and improved access t%li%diagnostic services als%li%support growth in this segment.

Based on end use, hospitals and diagnostic laboratories segment dominated the market and accounted for the largest share of 63.24% in 2024.Hospitals and diagnostic laboratories are key drivers in the prostate cancer biomarker industry due t%li%their central role in patient diagnosis, biopsy evaluation, and treatment planning. Increasing patient volumes, availability of advanced diagnostic infrastructure, and demand for accurate, early-stage detection tests like PSA, PHI, and ConfirmMDx fuel market growth. Additionally, integration of biomarker testing

+357 96 030922
info@marketpublishers.com

int%li%routine urology workflows and hospital-based cancer screening programs further enhances test adoption and market expansion in both developed and emerging regions.

North America dominates the prostate cancer biomarkers market due t%li%advanced diagnostic capabilities, early adoption of precision medicine, and supportive regulatory frameworks. Biomarker-based tests such as ExoDx Prostate (urine-based exosomal RNA test by Bio-Techne) and SelectMDx (mRNA test by MDxHealth) are widely utilized for biopsy decision-making. Additionally, clinical guidelines from the National Comprehensive Cancer Network (NCCN) endorse biomarker usage. Growing investment in genomics and partnerships between academic centers and biotech firms continue t%li%drive innovation and biomarker adoption across the region.

Asia Pacific region is expected t%li%witness fastest growth with a CAGR of 14.4% over the forecast period from 2025 t%li%2030, due t%li%increasing cancer awareness, improving healthcare infrastructure, and rising healthcare expenditure in countries like China, India, and Japan. Expanding access t%li%PSA screening and newer tests such as PHI and 4Kscore is driving early detection. Local governments are launching national cancer screening initiatives, and growing investments in precision medicine and molecular diagnostics are boosting biomarker adoption. Collaborations between regional hospitals and biotech firms are further fueling innovation and market expansion.

+357 96 030922
info@marketpublishers.com

Contents

CHAPTER 1 METHODOLOGY AND SCOPE

1.1 Market Segmentation and Scope
  1.1.1 Segment Definition
    1.1.1.1 Application Segment
    1.1.1.2 Type Segment
    1.1.1.3 End Use Segment
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
  1.4.1 Objective -
  1.4.2 Objective -
  1.4.3 Objective -
1.5 Research Methodology
1.6 Information Procurement
  1.6.1 Purchased Database
  1.6.2 Gvr's Internal Database
  1.6.3 Secondary Sources
  1.6.4 Primary Research
1.7 Information or Data Analysis
  1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
  1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations

CHAPTER 2 EXECUTIVE SUMMARY

2.1 Market Outlook
2.2 Application and Type Snapshot
2.3 End Use Snapshot
2.4 Competitive Landscape Snapshot

CHAPTER 3 PROSTATE CANCER BIOMARKERS MARKET VARIABLES, TRENDS, AND SCOPE

+357 96 030922
info@marketpublishers.com

3.1 Prostate Cancer Biomarkers Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Pipeline Analysis
3.3.1 Screening And Early Detection
3.3.2 Diagnosis And Risk Stratification
3.3.3 Prognosis And Treatment Monitoring
3.3.4 Companion Diagnostics
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Rising prevalence of prostate cancer
3.4.1.2 Advancements in Genomic and Proteomic Technologies
3.4.1.3 Supportive Government and Research Initiatives
3.4.2 Market Restraint Analysis
3.4.2.1 High Cost of Biomarker-Based Tests
3.4.2.2 Uneven Access to Advanced Diagnostic Infrastructure
3.5 Prostate Cancer Biomarkers: Market Analysis Tools
3.5.1 Industry Analysis - Porter’s
3.5.2 Pestle Analysis

CHAPTER 4 PROSTATE CANCER BIOMARKERS MARKET: SEGMENT ANALYSIS, BY TYPE, 2018 - 2030 (USD MILLION)

4.1 Prostate Cancer Biomarkers Market: Type Movement Analysis
4.1.1 Genetic Biomarkers
4.1.1.1 Genetic Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
4.1.2 Protein Biomarkers
4.1.2.1 Protein Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
4.1.3 Cell-Based Biomarkers
4.1.3.1 Cell-Based Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
4.1.5 Metabolomic Biomarkers
4.1.5.1 Metabolomic Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030, USD Million

CHAPTER 5 PROSTATE CANCER BIOMARKERS MARKET: SEGMENT ANALYSIS, BY APPLICATION, 2018 - 2030 (USD MILLION)

+357 96 030922
info@marketpublishers.com

5.1 Prostate Cancer Biomarkers Market: Application Movement Analysis
5.1.1 Screening And Early Detection
5.1.1.1 Screening And Early Detection Market, 2018 - 2030 (USD Million)
5.1.2 Diagnosis And Risk Stratification
5.1.2.1 Diagnosis And Risk Stratification Market, 2018 - 2030 (USD Million)
5.1.3 Prognosis And Treatment Monitoring
5.3.1 Prognosis And Treatment Monitoring Market, 2018 - 2030 (USD Million)
5.1.4 Companion Diagnostics
5.1.4.1 Companion Diagnostics Market, 2018 - 2030 (USD Million)

CHAPTER 6 PROSTATE CANCER BIOMARKERS MARKET: SEGMENT ANALYSIS, BY END USE, 2018 - 2030 (USD MILLION)

6.1 Prostate Cancer Biomarkers Market: End Use Movement Analysis
6.1.1 Hospitals And Diagnostic Laboratories
6.1.1.1 Hospitals And Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
6.1.2 Academic And Research Institutes
6.1.2.1 Academic And Research Institutes Market, 2018 - 2030 (USD Million)
6.1.3 Biopharmaceutical Companies
6.1.3.1 Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)

CHAPTER 7 PROSTATE CANCER BIOMARKERS MARKET: SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)

7.1 Regional Market Snapshot
7.2 North America
7.2.1 North America Prostate Cancer Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.2.2.2 Key Country Dynamics
7.2.2.3 Regulatory Framework
7.2.2.4 Reimbursement Scenario
7.2.3 Canada
7.2.3.1 Canada Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.2.3.2 Key Country Dynamics
7.2.3.3 Regulatory Framework
7.2.3.4 Reimbursement Scenario

+357 96 030922
info@marketpublishers.com

7.2.4 Mexico
7.2.4.1 Mexico Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.2.4.2 Key Country Dynamics
7.2.4.3 Regulatory Framework
7.2.4.4 Reimbursement Scenario
7.3 Europe
7.3.1 Europe Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.3.2 UK
7.3.2.1 UK Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.3.2.2 Key Country Dynamics
7.3.2.3 Regulatory Framework
7.3.2.4 Reimbursement Scenario
7.3.3 Germany
7.3.3.1 Germany Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.3.3.2 Key Country Dynamics
7.3.3.3 Regulatory Framework
7.3.3.4 Reimbursement Scenario
7.3.4 Spain
7.3.4.1 Spain Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.3.4.2 Key Country Dynamics
7.3.4.3 Regulatory Framework
7.3.4.4 Reimbursement Scenario
7.3.5 France
7.3.5.1 France Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.3.5.2 Key Country Dynamics
7.3.5.3 Regulatory Framework
7.3.5.4 Reimbursement Scenario
7.3.6 Italy
7.3.6.1 Italy Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.3.6.2 Key Country Dynamics
7.3.6.3 Regulatory Framework
7.3.6.4 Reimbursement Scenario
7.3.7 Denmark
7.3.7.1 Denmark Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.3.7.2 Key Country Dynamics
7.3.7.3 Regulatory Framework
7.3.7.4 Reimbursement Scenario
7.3.8 Sweden
7.3.8.1 Sweden Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)

+357 96 030922
info@marketpublishers.com

7.3.8.2 Key Country Dynamics
7.3.8.3 Regulatory Framework
7.3.8.4 Reimbursement Scenario
7.3.9 Norway
7.3.9.1 Norway Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.3.9.2 Key Country Dynamics
7.3.9.3 Regulatory Framework
7.3.9.4 Reimbursement Scenario
7.4 Asia Pacific
7.4.1 Asia-Pacific Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.4.2 Japan
7.4.2.1 Japan Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.4.2.2 Key Country Dynamics
7.4.2.3 Regulatory Framework
7.4.2.4 Reimbursement Scenario
7.4.3 China
7.4.3.1 China Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.4.3.2 Key Country Dynamics
7.4.3.3 Regulatory Framework
7.4.3.4 Reimbursement Scenario
7.4.4 India
7.4.4.1 India Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.4.4.2 Key Country Dynamics
7.4.4.3 Regulatory Framework
7.4.4.4 Reimbursement Scenario
7.4.5 South Korea
7.4.5.1 South Korea Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.4.5.2 Key Country Dynamics
7.4.5.3 Regulatory Framework
7.4.5.4 Reimbursement Scenario
7.4.6 Thailand
7.4.6.1 Thailand Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.4.6.2 Key Country Dynamics
7.4.6.3 Regulatory Framework
7.4.6.4 Reimbursement Scenario
7.4.7 Australia
7.4.7.1 Australia Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.4.7.2 Key Country Dynamics
7.4.7.3 Regulatory Framework

+357 96 030922
info@marketpublishers.com

7.4.7.4 Reimbursement Scenario
7.5 Latin America
7.5.1 Latin America Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.5.2.2 Key Country Dynamics
7.5.2.3 Regulatory Framework
7.5.2.4 Reimbursement Scenario
7.5.3 Argentina
7.5.3.1 Argentina Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.5.3.2 Key Country Dynamics
7.5.3.3 Regulatory Framework
7.5.2.4 Reimbursement Scenario
7.6 MEA
7.6.1 MEA Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.6.2.2 Key Country Dynamics
7.6.2.3 Regulatory Framework
7.6.2.4 Reimbursement Scenario
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.6.3.2 Key Country Dynamics
7.6.3.3 Regulatory Framework
7.6.3.4 Reimbursement Scenario
7.6.4 UAE
7.6.4.1 UAE Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.6.4.2 Key Country Dynamics
7.6.4.3 Regulatory Framework
7.6.2.4 Reimbursement Scenario
7.6.5 Kuwait
7.6.5.1 Kuwait Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
7.6.5.2 Key Country Dynamics
7.6.5.3 Regulatory Framework
7.6.5.4 Reimbursement Scenario

CHAPTER 8 PROSTATE CANCER BIOMARKERS MARKET: COMPETITIVE ANALYSIS

+357 96 030922
info@marketpublishers.com

8.1 Company Categorization
8.2 Strategy Mapping
8.2.1 New product launch
8.2.2 Partnerships
8.2.3 Acquisition
8.2.4 Collaboration
8.2.5 Funding
8.3 Company Market Share Analysis, 2022
8.4 Company Profiles
8.4.1 EXACT SCIENCES CORPORATION
8.4.1.1 Company overview
8.4.1.2 Financial performance
8.4.1.3 Product benchmarking
8.4.1.4 Strategic initiatives
8.4.2 MYRIAD GENETICS, INC.
8.4.2.1 Company overview
8.4.2.2 Financial performance
8.4.2.3 Product benchmarking
8.4.2.4 Strategic initiatives
8.4.3 BIO-TECHNE
8.4.3.1 Company overview
8.4.3.2 Financial performance
8.4.3.3 Product benchmarking
8.4.3.4 Strategic initiatives
8.4.4 EXODX
8.4.4.1 Company overview
8.4.4.2 Product benchmarking
8.4.4.3 Product benchmarking
8.4.4.4 Strategic initiatives
8.4.5 OPKO HEALTH,INC.
8.4.5.1 Company overview
8.4.5.2 Product benchmarking
8.4.5.3 Strategic initiatives
8.4.6 MDXHEALTH
8.4.6.1 Company overview
8.4.6.2 Financial performance
8.4.6.3 Product benchmarking
8.4.6.4 Strategic initiatives
8.4.7 VERACYTE, INC.

+357 96 030922
info@marketpublishers.com

8.4.7.1 Company overview
8.4.7.2 Financial performance
8.4.7.3 Product benchmarking
8.4.7.4 Strategic initiatives
8.4.8 BECKMAN COULTER, INC.
8.4.8.1 Company overview
8.4.8.2 Product benchmarking
8.4.9 NUCLEIX
8.4.9.1 Company overview
8.4.9.2 Financial performance
8.4.9.3 Product benchmarking
8.4.9.4 Strategic initiatives
8.4.10 DIACARTA
8.4.10.1 Company overview
8.4.10.2 Product benchmarking
8.4.10.3 Strategic initiatives

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Prostate Cancer Biomarkers Market Size, Share & Trends Analysis Report By Type (Genetic Biomarkers, Cell-based Biomarkers, Metabolomic Biomarkers), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

Product link: https://marketpublishers.com/r/PD58C1F97E02EN.html

Price: US$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/PD58C1F97E02EN.html